Cancer diagnostics company NeoGenomics Inc (NASDAQ: NEO) announced on Monday that it has acquired Pathline, LLC, a New Jersey-based CLIA/CAP/NYS-certified laboratory.

This acquisition enhances NeoGenomics' commercial presence in the Northeast US, a rapidly growing region with historically low market penetration. The move accelerates the company's growth in molecular and hematology-oncology testing by establishing a local presence.

Pathline, founded in 2009, serves hospitals, cancer centres and physician practices, with 98% of its revenue coming from the Northeast. The company provides a broad range of subspecialty pathology services, including histopathology, immunohistochemistry, cytogenetics, flow cytometry and molecular pathology.

NeoGenomics anticipates strong revenue growth from the acquisition and expects substantial cost reductions from operational synergies, which will begin contributing to adjusted EBITDA in 2026.